Zeprumetostat: all 34 studies that test it

Page 1 of 1. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.

• Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingNCT07874425Phase 2
• A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaNot yet recruitingNCT07854639Phase 2
• Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingNCT07717242Phase 2
• A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte LeukemiaNot yet recruitingNCT07692529Phase 1
• Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell LymphomaNot yet recruitingNCT07615283Phase 1/2
• Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular LymphomaRecruitingNCT07555470Phase 2
• Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell LymphomaRecruitingNCT07502768Phase 1/2
• Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingNCT07493330Phase 1/2
• Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLRecruitingNCT07372352Phase 2
• SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell LymphomaNot yet recruitingNCT07347288Phase 2
• EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingNCT07339527Phase 1/2
• PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingNCT07294664Phase 2
• A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingNCT07230106Phase 2
• Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer SubjectsRecruitingNCT07175220Phase 2
• SHR2554 Combined With Endocrine Therapy in Advanced Breast CancerRecruitingNCT07125950Phase 2
• Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)Not yet recruitingNCT06712173Phase 1
• SHR-1701 Combined with SHR2554 and BP102 for MCRCNot yet recruitingNCT06679673Phase 2
• Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaRecruitingNCT06519526Phase 2
• A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular LymphomaNot yet recruitingNCT06368167Phase 2
• A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell LymphomaRecruitingNCT06173999Phase 1/2
• SHR2554 Clinical Study of Chidamide in the Treatment of T-cell LymphomaRecruitingNCT06122389Phase 3
• SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT05896046Phase 1/2
• A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
• Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell LymphomasRecruitingNCT04407741Phase 1/2
• A Study of TLN-254 in Participants With Relapsed or Refractory T-cell LymphomaActive, not recruitingNCT06733441Phase 1
• Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy SubjectsCompletedNCT06093945Phase 1
• A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult VolunteersCompletedNCT06010680Phase 1
• Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy SubjectsCompletedNCT05661591Phase 1
• Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy SubjectsCompletedNCT05592262Phase 1
• A Itraconazole Effect Study of SHR2554 on Healthy Chinese Adult SubjectsCompletedNCT04627129Phase 1
• A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult SubjectsCompletedNCT04577885Phase 1
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• A Food Effect Study of SHR2554 on Healthy Chinese Male Adult SubjectsCompletedNCT04335266Phase 1
• A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid NeoplasmsStatus unknownNCT03603951Phase 1

← Zeprumetostat overview